Do you use anti-microbial prophylaxis when you prescribe ibrutinib?

Traditionally, H.Zoster and PJP prophylaxis was more routinely administered in CLL patients receiving chemoimmunotherapy as these regimens were typically more myelosuppressive as well as immunosuppressive. In the era of the novel BCR receptor agents with the approval of ibrutinib and idelalisib and now BCL-2 inhibitor venetoclax, prophylactic medications have not been routinely employed. This is obviously an area of controversy (and physician preference/practice) but there is emerging data that ...